Clinical Trials

Mercer University Clinical Research Department is proud to offer a large number of clinical trials for patients and potential patients. Our researchers start new trials throughout the year, so the list is updated frequently. For questions regarding a specific clinical trial, please contact the Clinical Research Manager at 478-301-5846, and she will direct you to the appropriate study coordinator.
 

Cardiology                   

  1. CHAMP-HF - Observational Registry of Treatment Patterns in US Heart Failure Patients with Reduced Ejection Fraction
  2. HEART FID (1VIT15043) - A Randomized, Double  Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency

Infectious Disease

  1. GS-US-292-1825 - A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis
  2. GS-US-380-1490 - A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS- 9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
  3. GS-US-380-1844 - Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed
  4. GS-US-380-1878 - A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults
  5. GS-US-380-1961 - A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883 / Emtricitabine / Tenofovir Alafenamide (GS-9883/F/TAF) from Elvitegravir /Cobicistat / Emtricitabine / Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir /Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women
  6. GS-US-380-4030 - A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed 
  7. GS-US-380-4458 - A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of  Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults
  8. GS-US-380-4580 - A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
  9. GS-US-412-2055 - A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection
  10. GSK-Atlas (201585) - A study to compare two drugs (called Cabotegravir and Rilpivirine, as oral tablets followed by long-acting injections) to current regimens containing 3 HIV drugs.
  11. GSK-Atlas 2M (207966) - A study to compare two drugs (called Cabotegravir and Rilpivirine, as oral tablets followed by long-acting injections) to current regimens containing 3 HIV drugs.  
  12. GSK-FLAIR (201584) -  A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants
  13. GSK–LAI (116482) - A Phase IIb, dose ranging study of oral GSK1265744 in combination with nucleoside reverse transcriptase inhibitors for induction of HIV-1 virologic suppression followed by an evaluation of maintenance of virologic suppression when oral GSK1265744 is combined with oral rilpivirine in HIV-1 infected, antiretroviral therapy naive adult subjects
  14. GSK-POLAR (209035) - A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 infected Adults who areVirologically Suppressed and Participated in Study LAI116482
  15. GSK-SWORD-2 (201637) - A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-,NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed
  16. GSK-Tango (204862) - A Phase III, randomized, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who are virologically suppressed                                                                                                   
  17. DLS LONGITUDINAL HCV - The Quantitation of HCV RNA in Whole Blood Samples Obtained from Individual Subjects at Specific Time-Points During the Course of Treatment for Hepatitis C
  18. SWIMS – Sticking With It Middle and Southern Georgia
  19. STEP/YES – Youth Engagement & Sustained Care: Seek, Test, Treat and Retain for Youth and Young Adults Living with or at High Risk for Acquiring HIV